DUBLIN, June 30, 2025 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, announced that, on Friday, June 27, 2025, the U.S. Court of Appeals for the District of Columbia Circuit (the “Appeals Court”) affirmed a prior decision of the U.S. District Court for the District of Columbia (the “District Court”) in favor of the U.S. Food and Drug Administration (“FDA”) in a suit brought by Jazz Pharmaceuticals Inc. (“Jazz”) regarding the FDA's approval of LUMRYZTM, the first and only once-at-bedtime oxybate treatment for cataplexy or excessive daytime sleepiness in patients 7 years of age and older with narcolepsy.
ASL Strategic Value Fund wants the narcolepsy drugmaker to retain investment bankers and consider a sale.
The consensus price target hints at an 81.6% upside potential for Avadel (AVDL). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
6 Aug 2025 (In 1 month) Date | | 0.04 Cons. EPS | - EPS |
6 May 2025 Date | | - Cons. EPS | - EPS |
3 Mar 2025 Date | | - Cons. EPS | - EPS |
6 Nov 2024 Date | | - Cons. EPS | - EPS |
8 Aug 2024 Date | | - Cons. EPS | - EPS |
6 Aug 2025 (In 1 month) Date | | 0.04 Cons. EPS | - EPS |
6 May 2025 Date | | - Cons. EPS | - EPS |
3 Mar 2025 Date | | - Cons. EPS | - EPS |
6 Nov 2024 Date | | - Cons. EPS | - EPS |
8 Aug 2024 Date | | - Cons. EPS | - EPS |
Drug Manufacturers - Specialty & Generic Industry | Healthcare Sector | Gregory J. Divis Jr. CEO | NASDAQ (NMS) Exchange | 05337M104 Cusip |
IE Country | 188 Employees | - Last Dividend | - Last Split | 7 Jun 1996 IPO Date |
Avadel Pharmaceuticals plc is a biopharmaceutical firm based in the United States, with its headquarters in Dublin, Ireland. Initially founded as Flamel Technologies SA, the company underwent a name change to Avadel Pharmaceuticals plc in January 2017, signaling a new phase in its journey since its incorporation in 2015. The company specializes in developing and delivering pharmaceutical products, focusing on therapies that address unmet medical needs. Avadel Pharmaceuticals plc has carved a niche for itself in the biopharmaceutical industry through its innovative drug development programs and a commitment to improving the lives of patients suffering from various conditions.